Regulatory science focuses on ensuring that
scientifically valid techniques, tools, and models are available to
evaluate products and, subsequently, to inform regulatory actions that
promote optimal health outcomes (Hamburg, 2010; Norman, 2012).
The HPRC Regulatory Science Laboratory includes Clinical and Experimental laboratories.
The Clinical laboratory
includes 4 negative pressure rooms and 2 control rooms for conducting
clinical human laboratory research. The control rooms allow for
continuous monitoring of participants and are equipped with video
capabilities. The clinical laboratory is equipped with diverse
topography registries (e.g., e-cig, tobacco, hookah) for use in lab as
well as in field research. Routine collection of exhaled breath, saliva,
blood, urine, and buccal samples provides support for diverse FDA and
NIH supported grants and assures that scientifically valid tools are
used to inform regulatory actions.
The HPRC Experimental Laboratory, adjacent
to the Clinical laboratory, supports the processing, analysis, and
storage of biological samples collected at the Clinical Laboratory.
Analysis performed at this laboratory include CO, nicotine, and cotinine
measurements, and verification of drug use abstinence. Over 3,000
samples were processed at this state-of-the-art laboratory in FY22.
After initial validation, samples stored at the HPRC Experimental
Laboratory can be distributed to diverse other experimental laboratories
for studies such as DNA damage and mutation analysis, RNA sequencing,
gene and protein expression, and inflammation studies.
Click the links below to learn more about current tobacco regulatory research at HPRC:
Dr. Lurdes Queimado examines the health effects of traditional and emerging tobacco products using a broad combination of biological tools, including a novel DNA damage assay (q-PADDA) developed in her laboratory.
Dr. Amy Cohn examines the effects of menthol-flavored tobacco products and low nicotine cigarettes on addiction outcomes.
Dr. Evan Floyd examines product design characteristics and standards.
Dr. Amanda Kong investigates the role of the tobacco
retailer environment on tobacco use and tobacco-related health outcomes, and
she critically examines the potential for tobacco control policies to eliminate
or unintentionally exacerbate racialized and socioeconomic health inequities.
Dr. Jason Oliver examines novel pharmacological, behavioral, and technology-based interventions for tobacco use, as well as how the tobacco regulatory environment contributes to the etiology of nicotine dependence.
Dr. Erin Vogel examines the effects of tobacco-related social media content and marketing claims on young people's perceptions of and intentions to use tobacco products.